May 16 (Reuters) - GENENTECH:
* PHASE III IMPOWER150 STUDY SHOWED GENENTECH’S TECENTRIQ AND AVASTIN PLUS CARBOPLATIN AND PACLITAXEL HELPED PEOPLE WITH A SPECIFIC TYPE OF METASTATIC LUNG CANCER LIVE SIGNIFICANTLY LONGER COMPARED TO AVASTIN PLUS CARBOPLATIN AND PACLITAXEL
* GENENTECH - IN PHASE III IMPOWER150 STUDY, SURVIVAL ADVANTAGE FOR TECENTRIQ-AVASTIN COMBO REGIMEN WAS SEEN IN ALL EXPLORATORY PATIENT SUBGROUPS ANALYZED Source text for Eikon: Further company coverage:
